These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11476898)

  • 1. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
    Fridkis-Hareli M; Stern JN; Fugger L; Strominger JL
    Hum Immunol; 2001 Aug; 62(8):753-63. PubMed ID: 11476898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
    Krogsgaard M; Wucherpfennig KW; Cannella B; Hansen BE; Svejgaard A; Pyrdol J; Ditzel H; Raine C; Engberg J; Fugger L
    J Exp Med; 2000 Apr; 191(8):1395-412. PubMed ID: 10770805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M; Santambrogio L; Stern JN; Fugger L; Brosnan C; Strominger JL
    J Clin Invest; 2002 Jun; 109(12):1635-43. PubMed ID: 12070311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
    Wucherpfennig KW; Sette A; Southwood S; Oseroff C; Matsui M; Strominger JL; Hafler DA
    J Exp Med; 1994 Jan; 179(1):279-90. PubMed ID: 7505801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2.
    Mukku PV; Passmore D; Phan D; Nag B
    Mol Immunol; 1995 Jun; 32(8):555-64. PubMed ID: 7541890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.
    Vergelli M; Kalbus M; Rojo SC; Hemmer B; Kalbacher H; Tranquill L; Beck H; McFarland HF; De Mars R; Long EO; Martin R
    J Neuroimmunol; 1997 Aug; 77(2):195-203. PubMed ID: 9258250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.
    Fridkis-Hareli M; Neveu JM; Robinson RA; Lane WS; Gauthier L; Wucherpfennig KW; Sela M; Strominger JL
    J Immunol; 1999 Apr; 162(8):4697-704. PubMed ID: 10202010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes.
    Wucherpfennig KW; Hafler DA; Strominger JL
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8896-900. PubMed ID: 7568039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.
    Wucherpfennig KW; Catz I; Hausmann S; Strominger JL; Steinman L; Warren KG
    J Clin Invest; 1997 Sep; 100(5):1114-22. PubMed ID: 9276728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein.
    Gauthier L; Smith KJ; Pyrdol J; Kalandadze A; Strominger JL; Wiley DC; Wucherpfennig KW
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11828-33. PubMed ID: 9751750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis.
    Zang YC; Kozovska M; Aebischer I; Li S; Boehme S; Crowe P; Rivera VM; Zhang JZ
    Int Immunol; 1998 Jul; 10(7):991-8. PubMed ID: 9701037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications.
    Kozovska M; Zang YC; Aebischer I; Lnu S; Rivera VM; Crowe PD; Boehme SA; Zhang JZ
    Eur J Immunol; 1998 Jun; 28(6):1894-901. PubMed ID: 9645371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.
    Muraro PA; Vergelli M; Kalbus M; Banks DE; Nagle JW; Tranquill LR; Nepom GT; Biddison WE; McFarland HF; Martin R
    J Clin Invest; 1997 Jul; 100(2):339-49. PubMed ID: 9218510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.
    Hansen BE; Nielsen CH; Madsen HO; Ryder LP; Jakobsen BK; Svejgaard A
    Tissue Antigens; 2011 Mar; 77(3):229-34. PubMed ID: 21299528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.
    Bourdette DN; Chou YK; Whitham RH; Buckner J; Kwon HJ; Nepom GT; Buenafe A; Cooper SA; Allegretta M; Hashim GA; Offner H; Vandenbark AA
    J Immunol; 1998 Jul; 161(2):1034-44. PubMed ID: 9670985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions.
    Godkin AJ; Smith KJ; Willis A; Tejada-Simon MV; Zhang J; Elliott T; Hill AV
    J Immunol; 2001 Jun; 166(11):6720-7. PubMed ID: 11359828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
    Li Y; Li H; Martin R; Mariuzza RA
    J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
    Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
    Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.
    Fridkis-Hareli M; Rosloniec EF; Fugger L; Strominger JL
    Hum Immunol; 2000 Jul; 61(7):640-50. PubMed ID: 10880734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.
    Stern JN; Illés Z; Reddy J; Keskin DB; Fridkis-Hareli M; Kuchroo VK; Strominger JL
    Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1620-5. PubMed ID: 15665083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.